Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology